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The work of Finegold et al. should be applauded as an advance in communicating the true harms of therapies in a fashion understandable by both clinicians and patients. 1 The concept of 'proportion of symptoms nonpharmacological' (PSN) mathematically weighs the probability of an adverse event during active treatment against the probability of the same adverse event during placebo therapy. As such, it can be considered an extension of the concept of number needed to harm (NNH), which also takes into account the probability of the adverse effect occurring with and without therapy, i.e. attributable risk. The new metric can improve clinician and patient understanding of the risks in comparison to benefit. An alternative approach related to PSN was proposed in 1996, applied under diverse clinical trial conditions and termed 'Unqualified Success' (US) and 'Unmitigated Failure' (UF). 2, 3 The former conveys the effort to achieve benefit of therapy without incurring a side effect and the latter conveys the situation of incurring a side effect without incurring any benefit. Both are also extensions of the number needed to treat (NNT) and NNH concepts and these extensions are achieved, as in PSN, by considering attributable risk but also benefit. Thus,
where P 1 is the control group event rate, P 2 is the treatment group event rate, Q 1 is the control group adverse event rate, Q 2 is the treatment group adverse event rate and the term (Q 2 À Q 1 ), a fundamental component of PSN, is the attributable risk of harm. Using values provided by Finegold et al. for placebo controlled statin trials in primary prevention with respect to prevention of death from any cause and as juxtaposed to the adverse outcome of significant liver transaminase elevations or newly diagnosed diabetes mellitus, the results are as follows:
NNT US (prevent death without incurring liver transaminase elevation) ¼ 193 patients NNT US (prevent death without incurring newly diagnosed diabetes) ¼ 194 patients NNH UF (liver transaminase Elevation without preventing death) ¼ 8703 patients NNH UF (new onset diabetes without preventing death) ¼ 6068 patients.
The ratios from these calculations are 45 and 31, respectively, and would be more if benefit and risks were weighted based on quality of life issues or costs. 2, 3 Thus, the work of Finegold et al. adds to the field by attempting to distill the risks of therapy from those associated with placebo as do other metrics such as NNT US and NNH UF . Such approaches are important to assist clinicians and patients in understanding risks and benefits of important therapies associated with side effects.
